Please login to the form below
Marstacimab
This page shows the latest Marstacimab news and features for those working in and with pharma, biotech and healthcare.
Pfizer doses first patient in investigational haemophilia drug trial
It will compare marstacimab to a run-in period on replacement therapy with VIII or IX clotting factor, respectively, or bypass therapy. ... Marstacimab offers a new way of treating haemophilia that does not rely on replacing factor VIII or factor IX.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- Merck sues US government over Medicare drug price negotiation programme
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
